Medlab’s cannabinoid treatment study shows 55% reduction in patient pain scores

Medlab’s latest progress report on its ongoing 12-month real-world observational study of cannabinoid treatment NanaBis for cancer-induced bone pain has demonstrated a 55% reduction in pain scores among the patient cohort.

Consistent with the company’s November 2020 update and the results from an earlier Phase I/II study undertaken at Sydney’s Royal North Shore Hospital, the report demonstrated the reduction in pain scores along with significant improvements in quality of life outcomes such as “general activities”, “sleep” and “mood”.